Primary Care Diabetes
Volume 4, Issue 1 , Pages 9-15 , April 2010

Reviewing statin therapy in diabetes—Towards the best practise

Received 6 April 2009 ,Revised 28 December 2009 ,Accepted 8 January 2010.

References 

  1. The global challenge of diabetes. Lancet. 2008;371:1723
  2. Taskinen MR. Type 2 diabetes as a lipid disorder. Curr. Mol. Med. 2005;5:297–308
  3. Keech A, Colquhoun D, Best J, et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care. 2003;26:2713–2721
  4. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J. Am. Coll. Cardiol. 2004;44:720–732
  5. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 2003;348:383–393
  6. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N. Engl. J. Med. 2008;358:580–591
  7. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–2016
  8. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–696
  9. Cholesterol Treatment Trialists’ (CTT) Collaborators , Kearney PM, Blackwell L, Collins R, Keech A, Simes J, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117–125
  10. American Diabetes Association . Standards of medical care in diabetes—2009. Diabetes Care. 2009;32:S13–S61
  11. Donnelly LA, Doney AS, Morris AD, et al. Long-term adherence to statin treatment in diabetes. Diabet. Med. 2008;25:850–855
  12. Laing SP, Swerdlow AJ, Slater SD, et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia. 2003;46:760–765
  13. Skrivarhaug T, Bangstad HJ, Stene LC, et al. Long-term mortality in a nationwide cohort of childhood-onset type 1 diabetic patients in Norway. Diabetologia. 2006;49:298–305
  14. Margeirsdottir HD, Larsen JR, Brunborg C, et al. High prevalence of cardiovascular risk factors in children and adolescents with type 1 diabetes: a population-based study. Diabetologia. 2008;51:554–561
  15. Retnakaran R, Zinman B. Type 1 diabetes, hyperglycaemia, and the heart. Lancet. 2008;371:1790–1799(see comment)
  16. Young MJ, McCardle JE, Randall LE, Barclay JI. Improved survival of diabetic foot ulcer patients 1995–2008: possible impact of aggressive cardiovascular risk management. Diabetes Care. 2008;31:2143–2147
  17. Wright RJ, Frier BM. Vascular disease and diabetes: is hypoglycaemia an aggravating factor?. Diabetes Metab. Res. Rev. 2008;24:353–363
  18. Fried LF, Forrest KY, Ellis D, et al. Lipid modulation in insulin-dependent diabetes mellitus: effect on microvascular outcomes. J. Diabetes Complications. 2001;15:113–119
  19. Bloomgarden ZT. Diabetic retinopathy and diabetic neuropathy. Diabetes Care. 2007;30:760–765
  20. Medina RJ, O’Neill CL, Devine AB, et al. The pleiotropic effects of simvastatin on retinal microvascular endothelium has important implications for ischaemic retinopathies. PLoS ONE. 2008;3:e2584
  21. Al-Shabrawey M, Bartoli M, El-Remessy AB, et al. Role of NADPH oxidase and Stat3 in statin-mediated protection against diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 2008;49:3231–3238
  22. Sen K, Misra A, Kumar A, Pandey RM. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res. Clin. Pract. 2002;56:1–11
  23. Gupta A, Gupta V, Thapar S, Bhansali A. Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. Am. J. Ophthalmol. 2004;137:675–682
  24. Zhang J, McGwin G. Association of statin use with the risk of developing diabetic retinopathy. Arch. Ophthalmol. 2007;125:1096–1099
  25. Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007;370:1687–1697
  26. Chew EY, Ambrosius WT, Howard LT, et al. Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE). Am. J. Cardiol. 2007;99:103111–104111
  27. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 2005;353:238–248
  28. Agarwal R. Effects of statins on renal function. Mayo Clin. Proc. 2007;82:1381–1390
  29. Chan DT, Irish AB, Dogra GK, Watts GF. Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials. Atherosclerosis. 2008;196:823–834
  30. Athyros VG, Kakafika AI, Karagiannis A, Mikhailidis DP. Do we need to consider inflammatory markers when we treat atherosclerotic disease?. Atherosclerosis. 2008;200:1–12
  31. Davis TM, Yeap BB, Davis WA, Bruce DG. Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study. Diabetologia. 2008;51:562–566
  32. Oltman CL, Davidson EP, Coppey LJ, et al. Attenuation of vascular/neural dysfunction in Zucker rats treated with enalapril or rosuvastatin. Obesity (Silver Spring). 2008;16:82–89
  33. Ii M, Nishimura H, Kusano KF, et al. Neuronal nitric oxide synthase mediates statin-induced restoration of vasa nervorum and reversal of diabetic neuropathy. Circulation. 2005;112:93–102
  34. Fegan PG, Shore AC, Mawson D, et al. Microvascular endothelial function in subjects with Type 2 diabetes and the effect of lipid-lowering therapy. Diabet. Med. 2005;22:1670–1676
  35. Beishuizen ED, Tamsma JT, Jukema JW, et al. The effect of statin therapy on endothelial function in type 2 diabetes without manifest cardiovascular disease. Diabetes Care. 2005;28:1668–1674
  36. van Venrooij FV, van de Ree MA, Bots ML, et al. Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial. Diabetes Care. 2002;25:1211–1216
  37. Dogra G, Watts G, Chan D, Stanton K. Statin therapy improves brachial artery vasodilator function in patients with Type 1 diabetes and microalbuminuria. Diabet. Med. 2005;22:239–242
  38. Mullen MJ, Wright D, Donald AE, et al. Atorvastatin but not l-arginine improves endothelial function in type I diabetes mellitus: a double-blind study. J. Am. Coll. Cardiol. 2000;36:410–416
  39. Janatuinen T, Knuuti J, Toikka JO, et al. Effect of pravastatin on low-density lipoprotein oxidation and myocardial perfusion in young adults with type 1 diabetes. Arterioscler. Thromb. Vasc. Biol. 2004;24:1303–1308
  40. Brumeanu TD, Goldstein R, Casares S. Down-regulation of autoreactive T-cells by HMG CoA reductase inhibitors. Clin. Immunol. 2006;119:1–12
  41. Jialal I, Miguelino E, Griffen SC, Devaraj S. Concomitant reduction of low-density lipoprotein-cholesterol and biomarkers of inflammation with low-dose simvastatin therapy in patients with type 1 diabetes. J. Clin. Endocrinol. Metab. 2007;92:3136–3140
  42. Diabetes Atorvastin Lipid Intervention (DALI) Study Group . The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care. 2001;24:1335–1341
  43. Armitage J. The safety of statins in clinical practice. Lancet. 2007;370:1781–1790
  44. SEARCH Collaborative G, Link E, Parish S, et al. N. Engl. J. Med. 2008;359:789–799
  45. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet. Genom. 2006;16:873–879
  46. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther. 2007;82:726–733
  47. Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin. Pharmacol. Ther. 2006;80:356–366
  48. Laaksonen R, Katajamaa M, Paiva H, et al. A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PLoS ONE. 2006;1:e97
  49. ACCORD Study Group , Buse JB, Bigger JT, et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am. J. Cardiol. 2007;99:2133-33i

PII: S1751-9918(10)00006-9

doi: 10.1016/j.pcd.2010.01.005

Primary Care Diabetes
Volume 4, Issue 1 , Pages 9-15 , April 2010

Article Tools

* Image Usage & Resolution